Metformin Aurobindo (Metformin Hydrochloride)

Metformin Aurobindo belongs to the biguanide class and is employed in the management of disorders of glucose metabolism.

• Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels and helps achieve target HbA1c.
• Prediabetes (impaired glucose tolerance): delays progression to overt diabetes when combined with lifestyle modification.
• Polycystic ovary syndrome (off‑label in some regions): may improve insulin resistance and menstrual regularity.

• Metformin Hydrochloride decreases hepatic gluconeogenesis, reduces intestinal glucose absorption, and enhances peripheral insulin sensitivity by activating AMP‑activated protein kinase (AMPK). These actions collectively lower circulating glucose without stimulating insulin secretion, helping to control hyperglycaemia in type 2 diabetes.

Metformin Aurobindo may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Diarrhoea: watery stools, often early in therapy.
• Abdominal discomfort: cramping or bloating.
• Metallic taste: transient alteration of taste perception.
• Decreased appetite: reduced desire to eat.
• Vitamin B12 deficiency: long‑term use may lower levels.

Serious or Rare Side Effects

• Lactic acidosis: rare but life‑threatening metabolic acidosis.
• Severe hypoglycaemia: usually when combined with insulin or sulfonylureas.
• Hepatic failure: worsening liver function may precipitate toxicity.
• Allergic reactions: rash, pruritus, or angio‑edema.
• Myopathy: muscle pain or weakness in rare cases.
• Electrolyte disturbances: especially with dehydration.

Metformin Aurobindo requires careful patient assessment and monitoring.

• Renal function: assess creatinine clearance before initiation and periodically thereafter.
• Hepatic function: evaluate liver enzymes to reduce risk of lactic acidosis.
• Cardiovascular status: avoid in patients with unstable or acute heart failure.
• Elderly patients: start at lower doses and monitor for accumulation.
• Concomitant alcohol use: limit intake to minimise lactic acidosis risk.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Metformin Aurobindo can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure and increase lactic acidosis risk.
• Cimetidine: can raise metformin plasma concentrations.
• Alcohol excess: enhances risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycaemia symptoms.
• Diuretics (especially thiazides): can affect renal clearance of metformin.
• ACE inhibitors/ARBs: monitor renal function when combined.
• Warfarin: may require INR monitoring.
• Antiretroviral agents (e.g., protease inhibitors): may increase metformin levels.